Gepirone
Top View
- Discovery of Novel Indolealkylpiperazine Derivatives As Potent 5-HT1A Receptor Agonists for the Potential Future Treatment of Depression
- PASS Information
- Chronic Treatment with the 5-HT1A Receptor Partial Agonist Tandospirone Increases Hippocampal Neurogenesis
- (ATC) Classification Codes for Antidepressants
- Antiemetic Effects of Serotonergic 5-HT1A-Receptor Agonists in Suncus Murinus
- Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: a Narrative Review of the Experimental Evidence
- Serotonin1a Receptor Activation by Flesinoxan in Humans Body Temperature and Neuroendocrine Responses B
- Azapirones for the Treatment of Anxiety – an Overview
- Effects of Chronic Buspirone Treatment on Cocaine Self-Administration
- Neurobiological Similarities in Depression and Drug Dependence: a Self-Medication Hypothesis Athina Markou, Ph.D., Thomas R
- Randomized, Placebo-Controlled Trials of Antidepressants for Acute Major Depression: Thirty-Year Meta-Analytic Review
- Table [1]: Definition of Reported Outcomes Study Outcome
- FDA Briefing Document Psychopharmacologic
- 43 Antidepressants Maurizio Fava, MD, and George I
- Gepirone Hydrochloride Extended-Release Tablets NDA #21-164
- The Use of Gepirone for Preparing a Pharmaceutical Composition for Alleviation of Primary Depressive Disorders
- Azapirones for the Treatment of Anxiety – an Overview
- The 5-HT1A Receptor and the Stimulus Effects of LSD in the Rat